'Recurrent vte' presentation slideshows

New Insights into the Definitive Management of VTE

New Insights into the Definitive Management of VTE. Understanding the Burden of VTE. Population-Based Studies: High Incidence of VTE. VTE: An Important Problem Among Hospital Patients. Percentage of Patients at Risk for VTE by Country.

960 views • 78 slides

All things thrombosis

649 views • 58 slides

Treatment of DVT/PE (VTE) Update 2010 L. Bernardo Menajovsky, MD, MS.

694 views • 51 slides

New (Direct)Oral anti-coagulants in the treatment of VTE

New (Direct)Oral anti-coagulants in the treatment of VTE. Dr NA Smith - Haematology Dept Heart of England NHS Foundation Trust. Venous thromboembolism (VTE). DVT. PE. Deep vein insufficiency. Post-thrombotic syndrome. Pulmonary hypertension. Death. Venous Ulcers.

492 views • 48 slides

The DASH Study

The DASH Study. Patrick Leonberger MSIV BGSMC Nov 8, 2013. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) Tosetto et al. Journal of Thrombosis and Haemostasis 2012. Goal of study.

579 views • 43 slides

????? Thrombophilia

1.07k views • 41 slides

Thrombosis in Cancer An Update on Risk Assessment, Prevention and Treatment

Thrombosis in Cancer An Update on Risk Assessment, Prevention and Treatment. Agnes Lee, MD, MSc, FRCPC University of British Columbia, Vancouver, BC June 2011. Disclosure. Leo Pharma Sanofi aventis Pfizer Bayer Boehringer Ingelheim Daiichi Sankyo.

416 views • 37 slides

321 views • 31 slides

Treatment and Secondary Prevention of Cancer-Associated Thrombosis

Treatment and Secondary Prevention of Cancer-Associated Thrombosis. Supplement to Module 6. Overview. Introduction UFH as initial treatment for VTE LMWH as initial treatment for VTE Fondaparinux as initial treatment for VTE Transition to long-term therapy with vitamin K antagonists

307 views • 17 slides

In the name of GOD

240 views • 16 slides

Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first

Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first unprovoked event: results of the ASPIRE randomized controlled trial Brighton T, Eikelboom JW, Mann K, Mister R, Gallus A , Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J

352 views • 15 slides

Deep vein thrombosis Pulmonary embolism

503 views • 10 slides

Duration of Anticoagulation

Deep Vein Thrombosis. Duration of Anticoagulation. 5 Patients Categories. 1. First Episode:. Transient risk. 2. First Episode:. Concurrent cancer. 3. First Episode:. Idiopathic. 4. First Episode:. Thrombophilia or prognostic marker. 5. Recurrent DVT. Deep Vein Thrombosis.

295 views • 10 slides

AMPLIFY-EXT Symptomatic Recurrent VTE or VTE-Related Death

AMPLIFY-EXT Symptomatic Recurrent VTE or VTE-Related Death. Placebo. Cumulative Event Rate (%). Apixaban , 2.5 mg. Apixaban , 5 mg. Months. Agnelli G et al. N Engl J Med 2013;368:699-708. AMPLIFY-EXT Major or Clinically Relevant Nonmajor Bleeding. Apixaban , 5 mg.

291 views • 2 slides